期刊文献+

表观遗传DNA甲基化和组蛋白修饰与疾病关系的研究进展 被引量:14

Advances in the Relationship between Epigenetic DNA Methylation and Histone Modification with Diseases
下载PDF
导出
摘要 近年来,表观遗传修饰在许多重大疾病中的致病机制和临床应用的研究受到广泛关注。在表观遗传修饰中,DNA甲基化和组蛋白修饰调节剂作为疾病发生、发展和临床诊断治疗的生物标志物,而DNA甲基化水平的高低和组蛋白修饰位点的不同均可能对疾病产生影响,DNA甲基化导致抑癌基因转录失活,组蛋白的异常修饰与肿瘤发生、发展相关。因此,探讨DNA甲基化和组蛋白修饰与疾病的关系,在疾病治疗过程中寻找靶向标志物,更深入地研究疾病的致病机制,可为疾病的预防、诊断和治疗提供新途径。 In recent years, epigenetic modification has been widely concerned in the pathogenesis and clinical application of many major diseases. In the epigenetic modification, DNA methylation modulators and histone modulators are used as biomarkers for the development and clinical diagnosis of diseases, the different levels of DNA methylation and histone modification sites may affect the occurrence and development of the disease process. DNA methylation leads to inactivation of tumor suppressor genes, and histone abnormalities are associated with tumor development. Therefore, the study of DNA methylation and histone modification and disease, to find the targeted markers during treatment, a deeper study of the pathogenesis of the disease may provide a new way for the prevention, diagnosis and treatment.
出处 《医学综述》 2017年第16期3160-3163,3169,共5页 Medical Recapitulate
关键词 表观遗传 DNA甲基化 组蛋白修饰 Epigenetics DNA methylation Histone modification
  • 相关文献

参考文献4

二级参考文献54

  • 1Gen Tamura.Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer[J].World Journal of Gastroenterology,2006,12(2):192-198. 被引量:107
  • 2马晓杰,李景鹏,赵勇.血浆中游离核酸:分子诊断的新靶点[J].生命的化学,2006,26(2):147-149. 被引量:4
  • 3赵成海,张宁,卜献民,李岩,张海鹏.胃癌多基因甲基化状态分析[J].世界华人消化杂志,2006,14(10):1004-1007. 被引量:7
  • 4张丽丽,吴建新.DNA甲基化——肿瘤产生的一种表观遗传学机制[J].遗传,2006,28(7):880-885. 被引量:54
  • 5Audergon PN, Catania S, Kagansky A, et al. Epigenetics. Restricted epigenetic inheritance of H3K9 methylation[J]. Science, 2015, 348(6230): 132-5.
  • 6Wu Y, Sarkissyan M, Vadgama JV. Epigeneties in breast and prostate cancer[J]. Methods Mol Biol, 2015, 1238: 425-46.
  • 7. Glasspool RM, Brown R, Gore ME, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs. carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer[J]. Br J Cancer, 2014, 110(8): 1923-9.
  • 8Yin X, Xiang T, Li L, et al. DACT1, an antagonist to Wnt/[3-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer[J]. Breast Cancer Res, 2013, ! 5(2): R23.
  • 9Borges S, D6ppler H, Perez EA, et al. Pharmacologic reversion of epigenetie silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis[J]. Breast Cancer Res, 2013, 15(2): R66.
  • 10Ari F, Napieralski R, Ulukaya E, et al. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthraeycline-based chemotherapy and the demethylating agent decitabine[J]. Cell Biochem Funct, 2011, 29(8): 651-9.

共引文献57

同被引文献142

引证文献14

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部